Atea Pharmaceuticals Inc

NASDAQ:AVIRUnited States

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in developing its product candidate, bemnifosbuvir, for the treatment of coronavirus disease 2019 (COVID-19), and its variants. The Company is also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV). The bemnifosbuvir (AT-527) for COVID-19 addresses key limitations of current therapies and explores combination therapy for specific patient populations. Bemnifosbuvir is an investigational, orally administered, non-mutagenic, non-teratogenic, direct-acting antiviral agent. The Company's SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy but also explores the effect of combination therapy in a smaller sub-set of patients who receive an antiviral drug along with bemnifosbuvir.

Contact Information

Headquarters

225 Franklin Street, Suite 2100BOSTON, MA, United States 02110

Phone

857-204-8109

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Founder

Jean-Pierre Sommadossi

Chief Financial Officer, Executive Vice President - Legal , Secretary

Andrea Corcoran

Executive Vice President, Chief Accounting Officer

Wayne Foster

Chief Development Officer

Janet Hammond

Chief Medical Officer

Maria Horga